Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-INH phase 3 study of fitusiran in hemophilia A or B with inhibitors
MOH_2018-05-22_002394Phase 3Not yet recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fitusiran in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Bleeding reduction efficacy. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on MOH_2018-05-22_002394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-22_002394.